Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07186595 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance
A Phase 4 study of Mid Face Volume Deficit, sponsored by AbbVie.
- Active
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 10
- Study locations
NCT07186595: Active Phase 4 study of Mid Face Volume Deficit, sponsored by AbbVie.
NCT07186595 is a Phase 4 study of Mid Face Volume Deficit that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 75 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07186595, a Phase 4 study of Mid Face Volume Deficit, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin quality.
Primary Outcome
The FACE-Q Satisfaction with Facial Appearance is a validated questionnaire that asks participants to report their level of satisfaction with the appearance of their face.
Conditions Studied
Interventions
- DEVICE JUVÉDERM VOLUX XC
- DEVICE JUVÉDERM VOLUMA XC
- DEVICE JUVÉDERM VOLBELLA XC
- DEVICE JUVÉDERM VOLLURE XC
- DEVICE SKINVIVE by JUVÉDERM
Study Locations (10)
California
- Kian Aesthetic Institute /ID# 277045 - Los Angeles
- West Dermatology La Jolla /ID# 277034 - San Diego
- Pacific Clinical Innovations /ID# 277026 - Vista
Louisiana
- H&H Research, LLC /ID# 277084 - Metairie
- DelRicht Research - New Orleans 308 /ID# 277039 - New Orleans
Florida
- Skin Research Institute LLC /ID# 277038 - Coral Gables
Georgia
- Monarch Plastic Surgery and Skin Renewal Center /ID# 278182 - Atlanta
Illinois
- Advanced Dermatology - Lincolnshire /ID# 277036 - Lincolnshire
Texas
- Bellaire Dermatology Associates /ID# 278180 - Bellaire
Virginia
- SkinDC /ID# 277062 - Arlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
What the registry record for NCT07186595 still lists
NCT07186595 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Mid Face Volume Deficit appearing as the primary indexed condition, and to 5 interventions - of which JUVÉDERM VOLUX XC is the first listed.
NCT07186595 lists 10 locations in 7 states (California, Louisiana, Florida).
Frequently Asked Questions
What is clinical trial NCT07186595 about?
NCT07186595 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance". The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin quality.
What is the current status of trial NCT07186595?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2025-09-25. Estimated completion is 2026-08.
What conditions does trial NCT07186595 study?
This clinical trial studies the following conditions: Mid Face Volume Deficit.
What interventions are being tested in trial NCT07186595?
The interventions under investigation include: JUVÉDERM VOLUX XC (DEVICE), JUVÉDERM VOLUMA XC (DEVICE), JUVÉDERM VOLBELLA XC (DEVICE), JUVÉDERM VOLLURE XC (DEVICE), SKINVIVE by JUVÉDERM (DEVICE).
Who is sponsoring clinical trial NCT07186595?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07186595 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mid Face Volume Deficit
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07186595's enrollment target sits among peer trials
75 1002nd of 2000 higher than 975 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI